Filing Details
NovoCure Ltd (NASDAQ:NVCR) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on October 29, 2026.
The Healthcare company reported Q0 revenue of .
10q filedNASDAQ:NVCR
NovoCure Ltd (NVCR) Files Quarterly Report for Q0
NovoCure Ltd (NASDAQ:NVCR) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on October 29, 2026.
At publication ·
What changed
NovoCure Ltd (NASDAQ:NVCR) · 10q filed
- Form
- 10-Q
At a glance
Key takeaways
- NovoCure Ltd filed its quarterly 10-Q report with the SEC on October 29, 2026.
- The company's stock trades at $13.11 with a market capitalization of $1.5 billion.
- The 10-Q filing contains unaudited financial statements and management commentary on business performance and emerging trends.
Market Context
NovoCure Ltd's stock currently trades at $13.11 with a market capitalization of $1.5B.
The 10-Q provides NovoCure Ltd's quarterly financial update, including unaudited financial statements and management commentary on recent performance. While less detailed than the annual 10-K, the 10-Q often contains timely information about emerging trends, updated risk factors, and changes in business conditions since the last filing.
All SEC filings for NovoCure Ltd are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View NVCR Stock Page
Frequently Asked Questions
Where can I read NVCR's SEC filings?
Browse all filings on our NVCR SEC filings page.
What types of SEC filings does NovoCure Ltd file?
Public companies like NovoCure Ltd file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.